Genomic Health, Inc.
GHDX today announced that, effective May 8, 2013, Palmetto GBA, the
designated national contractor for its Oncotype DX® breast cancer test, has
expanded its coverage policy for all qualified Medicare patients to include
patients with ductal carcinoma in situ (DCIS) following the recent publication
of the breast cancer test's DCIS Score in the peer-reviewed, Journal of the
National Cancer Institute.
The detection of DCIS is increasing in the United States, with more than
50,000 patients diagnosed each year. Most women with DCIS who receive
breast-conserving surgery without standard radiotherapy will not develop a
local recurrence, defined as either the recurrence of DCIS or the development
of a new invasive cancer in the same breast. The Oncotype DX DCIS Score
predicts 10-year local recurrence, DCIS or invasive carcinoma, based on a
patient's individualized underlying tumor biology regardless of whether
adjuvant tamoxifen is given, providing important information beyond
traditional clinical factors such as tumor size, grade, surgical margins, or
menopausal status.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in